Literature DB >> 18305152

TDP-43 regulates retinoblastoma protein phosphorylation through the repression of cyclin-dependent kinase 6 expression.

Youhna M Ayala1, Tom Misteli, Francisco E Baralle.   

Abstract

TDP-43 (for TAR DNA binding protein) is a highly conserved heterogeneous nuclear ribonucleoprotein (hnRNP) involved in specific pre-mRNA splicing and transcription events. TDP-43 recently has been identified as the main component of cytoplasmic inclusions in frontotemporal lobar degeneration (FTLD) and amyotrophic lateral sclerosis (ALS), two neurodegenerative disorders. The cellular role of this protein remains to be identified. Here, we show that loss of TDP-43 results in dysmorphic nuclear shape, misregulation of the cell cycle, and apoptosis. Removal of TDP-43 in human cells significantly increases cyclin-dependent kinase 6 (Cdk6) protein and transcript levels. The control of Cdk6 expression mediated by TDP-43 involves GT repeats in the target gene sequence. Cdk6 up-regulation in TDP-43-depleted cells is accompanied by an increase in phosphorylation of two of its major targets, the retinoblastoma protein pRb and pRb-related protein pRb2/p130. TDP-43 silencing also is followed by changes in the expression levels of several factors that control cell proliferation. Morphological nuclear defects and increased apoptosis upon TDP-43 loss are mediated via the pRb pathway because pRb-negative cells (Saos-2) do not undergo programmed cell death or nuclear shape deformation upon TDP-43 removal. Our results identify a regulatory target of TDP-43 and show that TDP-43 depletion has important consequences in essential metabolic processes in human cells.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18305152      PMCID: PMC2268791          DOI: 10.1073/pnas.0800546105

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  42 in total

1.  The apoptotic v-cyclin-CDK6 complex phosphorylates and inactivates Bcl-2.

Authors:  P M Ojala; K Yamamoto; E Castaños-Vélez; P Biberfeld; S J Korsmeyer; T P Mäkelä
Journal:  Nat Cell Biol       Date:  2000-11       Impact factor: 28.824

Review 2.  Regulation of G(1) cyclin-dependent kinases in the mammalian cell cycle.

Authors:  S V Ekholm; S I Reed
Journal:  Curr Opin Cell Biol       Date:  2000-12       Impact factor: 8.382

Review 3.  Where the cell cycle and histones meet.

Authors:  M E Ewen
Journal:  Genes Dev       Date:  2000-09-15       Impact factor: 11.361

Review 4.  The Rb/E2F pathway: expanding roles and emerging paradigms.

Authors:  J W Harbour; D C Dean
Journal:  Genes Dev       Date:  2000-10-01       Impact factor: 11.361

5.  Dysregulation of cyclin dependent kinase 6 expression in splenic marginal zone lymphoma through chromosome 7q translocations.

Authors:  M M Corcoran; S J Mould; J A Orchard; R E Ibbotson; R M Chapman; A P Boright; C Platt; L C Tsui; S W Scherer; D G Oscier
Journal:  Oncogene       Date:  1999-11-04       Impact factor: 9.867

6.  RB-dependent S-phase response to DNA damage.

Authors:  K E Knudsen; D Booth; S Naderi; Z Sever-Chroneos; A F Fribourg; I C Hunton; J R Feramisco; J Y Wang; E S Knudsen
Journal:  Mol Cell Biol       Date:  2000-10       Impact factor: 4.272

7.  Cells degrade a novel inhibitor of differentiation with E1A-like properties upon exiting the cell cycle.

Authors:  S Miyake; W R Sellers; M Safran; X Li; W Zhao; S R Grossman; J Gan; J A DeCaprio; P D Adams; W G Kaelin
Journal:  Mol Cell Biol       Date:  2000-12       Impact factor: 4.272

8.  A novel Rb- and p300-binding protein inhibits transactivation by MyoD.

Authors:  W R MacLellan; G Xiao; M Abdellatif; M D Schneider
Journal:  Mol Cell Biol       Date:  2000-12       Impact factor: 4.272

9.  Characterization and functional implications of the RNA binding properties of nuclear factor TDP-43, a novel splicing regulator of CFTR exon 9.

Authors:  E Buratti; F E Baralle
Journal:  J Biol Chem       Date:  2001-07-24       Impact factor: 5.157

10.  Nuclear factor TDP-43 and SR proteins promote in vitro and in vivo CFTR exon 9 skipping.

Authors:  E Buratti; T Dörk; E Zuccato; F Pagani; M Romano; F E Baralle
Journal:  EMBO J       Date:  2001-04-02       Impact factor: 11.598

View more
  105 in total

1.  Autoantibody signatures as biomarkers to distinguish prostate cancer from benign prostatic hyperplasia in patients with increased serum prostate specific antigen.

Authors:  Dennis J O'Rourke; Daniel A DiJohnson; Robert J Caiazzo; James C Nelson; David Ure; Michael P O'Leary; Jerome P Richie; Brian C-S Liu
Journal:  Clin Chim Acta       Date:  2011-11-29       Impact factor: 3.786

Review 2.  Gains or losses: molecular mechanisms of TDP43-mediated neurodegeneration.

Authors:  Edward B Lee; Virginia M-Y Lee; John Q Trojanowski
Journal:  Nat Rev Neurosci       Date:  2011-11-30       Impact factor: 34.870

Review 3.  TAR DNA-binding protein 43 in neurodegenerative disease.

Authors:  Alice S Chen-Plotkin; Virginia M-Y Lee; John Q Trojanowski
Journal:  Nat Rev Neurol       Date:  2010-03-16       Impact factor: 42.937

4.  Transcription factors expressed in olfactory bulb local progenitor cells revealed by genome-wide transcriptome profiling.

Authors:  Gordon R O Campbell; Ariane Baudhuin; Karen Vranizan; John Ngai
Journal:  Mol Cell Neurosci       Date:  2010-12-29       Impact factor: 4.314

5.  Tat-activating regulatory DNA-binding protein regulates glycolysis in hepatocellular carcinoma by regulating the platelet isoform of phosphofructokinase through microRNA 520.

Authors:  Yun-Yong Park; Sang-Bae Kim; Hee Dong Han; Bo Hwa Sohn; Ji Hoon Kim; Jiyong Liang; Yiling Lu; Cristian Rodriguez-Aguayo; Gabriel Lopez-Berestein; Gordon B Mills; Anil K Sood; Ju-Seog Lee
Journal:  Hepatology       Date:  2013-05-15       Impact factor: 17.425

Review 6.  TDP-43/FUS in motor neuron disease: Complexity and challenges.

Authors:  Erika N Guerrero; Haibo Wang; Joy Mitra; Pavana M Hegde; Sara E Stowell; Nicole F Liachko; Brian C Kraemer; Ralph M Garruto; K S Rao; Muralidhar L Hegde
Journal:  Prog Neurobiol       Date:  2016-09-28       Impact factor: 11.685

Review 7.  Alternative splicing and disease.

Authors:  Jamal Tazi; Nadia Bakkour; Stefan Stamm
Journal:  Biochim Biophys Acta       Date:  2008-10-17

8.  Astrocytic TDP-43 pathology in Alexander disease.

Authors:  Adam K Walker; Christine M LaPash Daniels; James E Goldman; John Q Trojanowski; Virginia M-Y Lee; Albee Messing
Journal:  J Neurosci       Date:  2014-05-07       Impact factor: 6.167

Review 9.  The role of transactive response DNA-binding protein-43 in amyotrophic lateral sclerosis and frontotemporal dementia.

Authors:  Ian R A Mackenzie; Rosa Rademakers
Journal:  Curr Opin Neurol       Date:  2008-12       Impact factor: 5.710

10.  TDP-43 mutant transgenic mice develop features of ALS and frontotemporal lobar degeneration.

Authors:  Iga Wegorzewska; Shaughn Bell; Nigel J Cairns; Timothy M Miller; Robert H Baloh
Journal:  Proc Natl Acad Sci U S A       Date:  2009-10-15       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.